Home > News > Case Study

Fully Optimised Aptamers

Introducing OptimersTM
3rd October 2018
 
Proprietary process with validated improvement in delivery and performance

OptimersTM in 12 weeks
Aptamer Group is pleased to announce availability of  OptimersTM – the new standard for our custom development services.

Aptamer Group is dedicated to continually improve its service offerings to identify the best reagent(s) from within our vast aptamer libraries in the […]

Aptamer Stability

29th August 2018
At Aptamer Group, every custom aptamer project begins with a feasibility study. The target and assay matrix are tested for compatibility and stability with the aptamer library, under a variety of conditions. At this early stage it is important to understand the optimal strategy for the selection, address any potential issues and […]

Aptamer Group Secures $2.2m Series A Investment

Arron Tolley, CEO – I’m delighted to announce that Aptamer Group Ltd, has recently closed its Series A investment round; attracting international interest and securing $2.2m of funding from overseas investors, to support its pioneering aptamer development pipeline.

Aptamer technology is rapidly evolving and will continue to have a significant impact on the life sciences market […]

Congratulations to Dr Mateja Vidic

1st June 2018

We are very pleased to announce that Mateja Vidic has completed and been awarded her PhD for the Development of DNA Aptamers Specific for Non-Small Cell Lung Cancer by the University of Ljubljana, Slovenija. Her experience in aptamer selection and application is a valuable asset to our lab and we are very proud […]

Spotlight: Laboratory Technician, Katriona Harrison

Working at Aptamer Group:
The continued success of Aptamer Group means that the scientific team continues to grow. One member who joined us this summer is Katriona.  Now she has had the chance to establish herself, we took the opportunity to catch up with her.

Hi Katriona, please tell us a little about yourself.

I am currently a […]

  • Monoclonal data for aptamer selection in complex media

Aptamer Selection in Complex Media

25th August, 2017
Starting with the end in mind
The use of aptamers in point of care diagnostic devices, for monitoring drug dose levels or for use as therapeutics, requires functionality across a wide variety of conditions.

Aptamer selection starts in conditions optimised to promote aptamer/target interaction to identify the best target-binders. Subsequently, by introducing different pressures, we […]

  • Aptamer affinity, aptamer selection

AptaBasics: Aptamer Affinity

18th July, 2017
Aptamer Affinity
Aptamers are affinity reagents, so the mechanism of binding to a target is a key characteristic. Today we discuss how aptamers bind and outline what we do to ensure that they are fit-for-purpose.

Aptamers bind to their target through weak noncovalent forces such as; hydrogen bonding, Van der Waals and electrostatics. These occur […]

  • Small Molecule Target Aptamer Selection with Metabolite Counter Selection

Exquisite Selectivity Possible with Aptamers

30th May 2017
Exquisite Selectivity Possible with Aptamers

At Aptamer Group we can select aptamers that bind to small molecules. This is a key differentiator from antibodies where the target needs to be immunogenic. During selection it is possible to introduce counter-selection molecules to remove aptamers that will bind to moieties closely related to the target. Counter-selection drives […]